OMERS ADMINISTRATION Corp Has $974,000 Stock Position in Haleon plc (NYSE:HLN)

OMERS ADMINISTRATION Corp raised its stake in Haleon plc (NYSE:HLN - Free Report) by 454.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 102,100 shares of the company's stock after buying an additional 83,700 shares during the period. OMERS ADMINISTRATION Corp's holdings in Haleon were worth $974,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Sierra Ocean LLC bought a new position in shares of Haleon during the fourth quarter worth about $26,000. Geneos Wealth Management Inc. acquired a new stake in Haleon during the 4th quarter valued at approximately $35,000. FIL Ltd raised its holdings in Haleon by 45.7% during the 4th quarter. FIL Ltd now owns 4,049 shares of the company's stock worth $39,000 after purchasing an additional 1,270 shares during the last quarter. Spire Wealth Management bought a new position in Haleon during the 4th quarter worth approximately $39,000. Finally, Addison Advisors LLC lifted its position in shares of Haleon by 28.7% in the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock worth $47,000 after purchasing an additional 1,106 shares during the period. Institutional investors own 6.67% of the company's stock.

Haleon Stock Up 0.7%

HLN traded up $0.08 during midday trading on Wednesday, hitting $11.10. The company had a trading volume of 21,467,594 shares, compared to its average volume of 8,132,053. The stock's 50 day moving average price is $10.25 and its 200 day moving average price is $9.88. Haleon plc has a 52 week low of $8.25 and a 52 week high of $11.15. The company has a market capitalization of $50.02 billion, a price-to-earnings ratio of 32.63, a PEG ratio of 2.82 and a beta of 0.24. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The company had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. On average, research analysts anticipate that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The company also recently disclosed a -- dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be issued a dividend of $0.1166 per share. This is an increase from Haleon's previous -- dividend of $0.05. The ex-dividend date of this dividend is Friday, April 25th. This represents a dividend yield of 1.6%. Haleon's payout ratio is currently 58.97%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Hsbc Global Res cut shares of Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Morgan Stanley upgraded Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target for the company in a report on Friday, May 9th. HSBC reissued a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a research note on Monday, March 3rd. Finally, Barclays reiterated an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. Five investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $11.25.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.